Casi Pharmaceuticals Inc (CASI)

$1.26 -0.08 (-5.62%)
Market Cap 16.42M
Revenue (ttm) 28.54M
Net Income (ttm) -39.26M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -137.56%
Debt to Equity Ratio -0.92
Volume 20,500
Avg Vol 142,564
Day's Range N/A - N/A
Shares Out 12.30M
Stochastic %K 0%
Beta 0.90
Analysts Sell
Price Target $4.00

Company Profile

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma. The company's hematology/oncology assets in pipeline include CNCT19, an autologous CD19 CAR-T investiga...

Industry: Biotechnology
Sector: Healthcare
Phone: 86 10 6508 6063
Address:
1701-1702, China Central Office Tower 1, No. 81 Jianguo Road Chaoyang District, Beijing, China
BEATOFtheMARKET
BEATOFtheMARKET Nov. 11 at 2:55 PM
Results List 11/2025 with 13 trading days to go for this list. $CACC $CASI $BTU $BUD $BTDR
0 · Reply
TwongStocks
TwongStocks Nov. 10 at 9:07 PM
$CASI CASI Pharmaceuticals Receives and Appeals Delisting Determination from NASDAQ https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/casi-pharmaceuticals-receives-and-appeals-delisting-determination-fro-1099368 Delist letter received November 5. CASI appealed. The appeal will stay the suspension of the Company's securities pending the outcome of the appeal hearing.
0 · Reply
BillionerOfKing
BillionerOfKing Nov. 4 at 10:58 AM
$CASI Current Stock Price: $1.38 Contracts to trade: $2.5 CASI Nov 21 2025 Call Entry: $2.70 Exit: $5.02 ROI: 86% Hold ~25 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
DARKP00L
DARKP00L Nov. 3 at 2:44 PM
$CASI 09:15 on Nov. 03 2025 CASI Pharmaceuticals To Present Phase 1 CID-103 Data In Immune Thrombocytopenia At ASH 2025 #tradeideas
0 · Reply
eddiez69
eddiez69 Oct. 31 at 1:10 PM
$CASI This stock is on sale here at this price. I am buyer with limit orders. One piece of news and this will back over $2.00.
0 · Reply
Mr_Bill
Mr_Bill Oct. 29 at 7:34 PM
$CASI
0 · Reply
NVDAMillionaire
NVDAMillionaire Oct. 27 at 5:35 PM
$CASI Outstanding article that hits the mark on CASI's current state. So if you want to refresh your CASI insights or learn about CASI from scratch, this is a must read. https://beyondspx.com/quote/CASI/analysis/casi-pharmaceuticals-a-focused-future-on-cid-103-s-immunological-promise-nasdaq-casi
1 · Reply
eddiez69
eddiez69 Oct. 23 at 6:54 PM
$IMMX Volume on this indicates institutional accumulation. Long and strong! YO Small Cap Traders - you MUST LOOK at $CASI - mkt cap is $25.26 Million with only 1.84 Millions shares in float. The team is a who's who in biotech deals with David Cory, new CEO having brought many drugs to market and multiple Billion $ buyouts at other biotechs. Private Placement recently completed on 9/26 at higher price - Panacea and James Huang’s combined effective average cost is about $1.83 per share. No cash issues. Seriously big market for their drug. IMO this is a $7 stock easily See their 13D on edgar https://app.quotemedia.com/data/downloadFiling?webmasterId=102691&ref=319477051&type=HTML&symbol=CASI&cdn=9441db26338e6caf804c7ff41b11286b&companyName=CASI+Pharmaceuticals+Inc.&formType=SCHEDULE+13D&formDescription=General+statement+of+acquisition+of+beneficial+ownership&dateFiled=2025-09-26
0 · Reply
JGroove
JGroove Oct. 22 at 12:53 PM
$CASI guess I am bag holding until the next run
0 · Reply
JGroove
JGroove Oct. 15 at 3:24 PM
$CASI queued
0 · Reply
Latest News on CASI
CASI Pharmaceuticals Announces Third Quarter 2025 Business and Financial Results

Nov 14, 2025, 4:05 PM EST - 9 hours ago

CASI Pharmaceuticals Announces Third Quarter 2025 Business and Financial Results

CASI Pharmaceuticals Receives and Appeals Delisting Determination from NASDAQ

Nov 10, 2025, 4:05 PM EST - 4 days ago

CASI Pharmaceuticals Receives and Appeals Delisting Determination from NASDAQ

CASI Pharmaceuticals to Participate at Guggenheim Healthcare Innovation Conference

Nov 4, 2025, 9:00 AM EST - 10 days ago

CASI Pharmaceuticals to Participate at Guggenheim Healthcare Innovation Conference

CASI Pharmaceuticals Announces Upcoming Presentation of Clinical Results for CID-103 at the 67th American Society of Hematology (ASH) Annual Meeting

Nov 3, 2025, 9:01 AM EST - 11 days ago

CASI Pharmaceuticals Announces Upcoming Presentation of Clinical Results for CID-103 at the 67th American Society of Hematology (ASH) Annual Meeting

CASI Pharmaceuticals Appoints James Huang to Board of Directors

Sep 26, 2025, 9:45 AM EDT - 7 weeks ago

CASI Pharmaceuticals Appoints James Huang to Board of Directors

CASI Pharmaceuticals Announces Safety Monitoring Committee Recommendation to Escalate CID-103 Dose to Next Cohort in Phase 1 Immune Thrombocytopenia (ITP) Study

Sep 8, 2025, 9:00 AM EDT - 2 months ago

CASI Pharmaceuticals Announces Safety Monitoring Committee Recommendation to Escalate CID-103 Dose to Next Cohort in Phase 1 Immune Thrombocytopenia (ITP) Study

CASI Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 9:00 AM EDT - 2 months ago

CASI Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference

CASI Pharmaceuticals Appoints Barbara Krebs-Pohl, PhD to Board of Directors

Sep 2, 2025, 9:00 AM EDT - 2 months ago

CASI Pharmaceuticals Appoints Barbara Krebs-Pohl, PhD to Board of Directors

CASI Pharmaceuticals Announces Second Quarter 2025 Business and Financial Results

Aug 29, 2025, 4:05 PM EDT - 2 months ago

CASI Pharmaceuticals Announces Second Quarter 2025 Business and Financial Results

CASI Pharmaceuticals to Participate at Cantor Global Healthcare Conference 2025

Aug 28, 2025, 9:00 AM EDT - 2 months ago

CASI Pharmaceuticals to Participate at Cantor Global Healthcare Conference 2025

CASI Pharmaceuticals Announces FDA Clearance of IND Application for CID-103 in Renal Allograft Antibody-Mediated Rejection (AMR)

Aug 4, 2025, 9:00 AM EDT - 3 months ago

CASI Pharmaceuticals Announces FDA Clearance of IND Application for CID-103 in Renal Allograft Antibody-Mediated Rejection (AMR)

CASI Pharmaceuticals Appoints David Cory as Chief Executive Officer to Lead U.S. Company Focused on Clinical Development of CID-103, a Potential Best in Class Anti-CD38 Program

Jul 21, 2025, 4:05 PM EDT - 4 months ago

CASI Pharmaceuticals Appoints David Cory as Chief Executive Officer to Lead U.S. Company Focused on Clinical Development of CID-103, a Potential Best in Class Anti-CD38 Program

CASI Pharmaceuticals Provides Business and Clinical Update

May 19, 2025, 9:00 AM EDT - 6 months ago

CASI Pharmaceuticals Provides Business and Clinical Update

CASI Pharmaceuticals Announces First Quarter 2025 Business and Financial Results

May 16, 2025, 8:00 AM EDT - 6 months ago

CASI Pharmaceuticals Announces First Quarter 2025 Business and Financial Results

CASI Pharmaceuticals Enters Into Definitive Agreement for the Divestiture of Assets in China

May 12, 2025, 8:00 AM EDT - 6 months ago

CASI Pharmaceuticals Enters Into Definitive Agreement for the Divestiture of Assets in China

CASI Pharmaceuticals Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement

May 7, 2025, 8:00 AM EDT - 6 months ago

CASI Pharmaceuticals Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement

CASI Pharmaceuticals Announces Receipt of An Updated Non-Binding Proposal to Acquire Entire China Business of the Company

Apr 3, 2025, 8:00 AM EDT - 8 months ago

CASI Pharmaceuticals Announces Receipt of An Updated Non-Binding Proposal to Acquire Entire China Business of the Company

CASI Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Business and Financial Results

Mar 31, 2025, 8:15 AM EDT - 8 months ago

CASI Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Business and Financial Results

CASI Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Immune Thrombocytopenia

Jan 6, 2025, 8:00 AM EST - 11 months ago

CASI Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Immune Thrombocytopenia

CASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial Results

Nov 15, 2024, 8:00 AM EST - 1 year ago

CASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial Results

CASI Pharmaceuticals Receives CTA Approval From China's NMPA for CID-103 in Immune Thrombocytopenia

Oct 24, 2024, 8:00 AM EDT - 1 year ago

CASI Pharmaceuticals Receives CTA Approval From China's NMPA for CID-103 in Immune Thrombocytopenia

CASI PHARMACEUTICALS TO PARTICIPATE IN THE 2024 H.C. WAINWRIGHT GLOBAL INVESTMENT CONFERENCE

Sep 4, 2024, 8:00 AM EDT - 1 year ago

CASI PHARMACEUTICALS TO PARTICIPATE IN THE 2024 H.C. WAINWRIGHT GLOBAL INVESTMENT CONFERENCE

CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2024 BUSINESS AND FINANCIAL RESULTS

Aug 16, 2024, 8:00 AM EDT - 1 year ago

CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2024 BUSINESS AND FINANCIAL RESULTS

CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS

Jul 19, 2024, 5:30 PM EDT - 1 year ago

CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS

CASI Pharmaceuticals announces appointment of Daniel Lang, MD as CFO and SVP

Jul 8, 2024, 7:30 AM EDT - 1 year ago

CASI Pharmaceuticals announces appointment of Daniel Lang, MD as CFO and SVP

CASI Pharmaceuticals Announces Plan To Submit IND Application For CID-103, an Anti-CD 38 Antibody in Antibody-Mediated Rejection, and Receipt of a Non-Binding Proposal to Acquire Entire China Business of the Company

Jun 26, 2024, 4:15 PM EDT - 1 year ago

CASI Pharmaceuticals Announces Plan To Submit IND Application For CID-103, an Anti-CD 38 Antibody in Antibody-Mediated Rejection, and Receipt of a Non-Binding Proposal to Acquire Entire China Business of the Company

CASI Pharmaceuticals Announces $15 Million Private Placement Financing by Venrock Healthcare Capital Partners, Foresite Capital, Panacea Venture and Dr. Wei-Wu He

Jun 26, 2024, 4:10 PM EDT - 1 year ago

CASI Pharmaceuticals Announces $15 Million Private Placement Financing by Venrock Healthcare Capital Partners, Foresite Capital, Panacea Venture and Dr. Wei-Wu He

CASI Pharmaceuticals Receives FDA Clearance On The Investigational New Drug (IND) Application For CID-103 In Immune Thrombocytopenia (ITP)

May 15, 2024, 8:00 AM EDT - 1 year ago

CASI Pharmaceuticals Receives FDA Clearance On The Investigational New Drug (IND) Application For CID-103 In Immune Thrombocytopenia (ITP)

CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2024 BUSINESS AND FINANCIAL RESULTS

May 14, 2024, 8:00 AM EDT - 1 year ago

CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2024 BUSINESS AND FINANCIAL RESULTS

CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTS

Mar 28, 2024, 7:00 AM EDT - 1 year ago

CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTS

CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In China

Mar 5, 2024, 7:00 AM EST - 1 year ago

CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In China

CASI PHARMACEUTICALS ANNOUNCES FIRST DOSING OF FOLOTYN® IN CHINA

Feb 16, 2024, 7:00 AM EST - 1 year ago

CASI PHARMACEUTICALS ANNOUNCES FIRST DOSING OF FOLOTYN® IN CHINA

CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2023 BUSINESS AND FINANCIAL UPDATES

Nov 14, 2023, 7:00 AM EST - 2 years ago

CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2023 BUSINESS AND FINANCIAL UPDATES

CASI PHARMACEUTICALS ANNOUNCES MARKET APPROVAL OF CNCT19 BY CHINA NMPA

Nov 8, 2023, 7:00 AM EST - 2 years ago

CASI PHARMACEUTICALS ANNOUNCES MARKET APPROVAL OF CNCT19 BY CHINA NMPA

CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2023 BUSINESS AND FINANCIAL UPDATES

Aug 11, 2023, 7:00 AM EDT - 2 years ago

CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2023 BUSINESS AND FINANCIAL UPDATES

Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter Agreement to Transfer License of FOLOTYN® (Pralatrexate) in China to CASI Pharmaceuticals

Aug 1, 2023, 7:00 AM EDT - 2 years ago

Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter Agreement to Transfer License of FOLOTYN® (Pralatrexate) in China to CASI Pharmaceuticals

CASI Pharmaceuticals Acquires Global Intellectual Property Rights to Cleave Therapeutics' VCP/P97 Inhibitor CB-5339

Jul 20, 2023, 8:00 AM EDT - 2 years ago

CASI Pharmaceuticals Acquires Global Intellectual Property Rights to Cleave Therapeutics' VCP/P97 Inhibitor CB-5339

Cleave Therapeutics Announces Acquisition of Clinical and Preclinical Assets

Jul 20, 2023, 8:00 AM EDT - 2 years ago

Cleave Therapeutics Announces Acquisition of Clinical and Preclinical Assets

CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTS

May 17, 2023, 7:35 AM EDT - 2 years ago

CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTS

CASI Pharmaceuticals Files Annual Report on Form 20-F for Fiscal Year 2022

Apr 26, 2023, 9:49 AM EDT - 2 years ago

CASI Pharmaceuticals Files Annual Report on Form 20-F for Fiscal Year 2022

CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2022 FINANCIAL RESULTS

Apr 26, 2023, 7:00 AM EDT - 2 years ago

CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2022 FINANCIAL RESULTS

CASI PHARMACEUTICALS COMPLETES REDOMICILIATION MERGER

Mar 21, 2023, 4:30 PM EDT - 2 years ago

CASI PHARMACEUTICALS COMPLETES REDOMICILIATION MERGER

Casi Pharmaceuticals to run clinical trial for multiple myeloma drug in China

Jan 6, 2023, 8:42 AM EST - 3 years ago

Casi Pharmaceuticals to run clinical trial for multiple myeloma drug in China

CASI PHARMACEUTICALS AND CLEAVE THERAPEUTICS ANNOUNCE CLINICAL TRIAL APPLICATION APPROVAL FOR CB-5339 IN PATIENTS WITH MULTIPLE MYELOMA IN CHINA

Jan 6, 2023, 7:00 AM EST - 3 years ago

CASI PHARMACEUTICALS AND CLEAVE THERAPEUTICS ANNOUNCE CLINICAL TRIAL APPLICATION APPROVAL FOR CB-5339 IN PATIENTS WITH MULTIPLE MYELOMA IN CHINA

CASI PHARMACEUTICALS' PARTNER JUVENTAS ANNOUNCES NEW DRUG APPLICATION FOR CNCT19 ACCEPTED BY CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION

Dec 15, 2022, 7:00 AM EST - 3 years ago

CASI PHARMACEUTICALS' PARTNER JUVENTAS ANNOUNCES NEW DRUG APPLICATION FOR CNCT19 ACCEPTED BY CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION

CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2022 FINANCIAL RESULTS

Nov 14, 2022, 7:00 AM EST - 3 years ago

CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2022 FINANCIAL RESULTS

CASI PHARMACEUTICALS ANNOUNCES EXIT OF JUVENTAS INVESTMENT TO STRENGTHEN BALANCE SHEET

Sep 23, 2022, 7:00 AM EDT - 3 years ago

CASI PHARMACEUTICALS ANNOUNCES EXIT OF JUVENTAS INVESTMENT TO STRENGTHEN BALANCE SHEET

ALJ Regional Hldgs (NASDAQ:ALJJ), CASI Pharmaceuticals (NASDAQ:CASI) – $2.2 Million Bet On Terns Pharmaceuticals? Check Out These 4 Penny Stocks Insiders Are Buying

Sep 9, 2022, 10:32 AM EDT - 3 years ago

ALJ Regional Hldgs (NASDAQ:ALJJ), CASI Pharmaceuticals (NASDAQ:CASI) – $2.2 Million Bet On Terns Pharmaceuticals? Check Out These 4 Penny Stocks Insiders Are Buying

LDI TERN

CASI PHARMACEUTICALS AND BIOINVENT ANNOUNCE DOSING OF FIRST PATIENT IN BI-1206 PHASE 1 CLINICAL TRIAL FOR THE TREATMENT OF RELAPSED/REFRACTORY NON-HODGKIN'S LYMPHOMA IN CHINA

Sep 7, 2022, 7:00 AM EDT - 3 years ago

CASI PHARMACEUTICALS AND BIOINVENT ANNOUNCE DOSING OF FIRST PATIENT IN BI-1206 PHASE 1 CLINICAL TRIAL FOR THE TREATMENT OF RELAPSED/REFRACTORY NON-HODGKIN'S LYMPHOMA IN CHINA

CASI Pharmaceuticals And 2 Other Stocks Under $4 Insiders Are Aggressively Buying

Aug 29, 2022, 8:58 AM EDT - 3 years ago

CASI Pharmaceuticals And 2 Other Stocks Under $4 Insiders Are Aggressively Buying

HCWB HSDT

BEATOFtheMARKET
BEATOFtheMARKET Nov. 11 at 2:55 PM
Results List 11/2025 with 13 trading days to go for this list. $CACC $CASI $BTU $BUD $BTDR
0 · Reply
TwongStocks
TwongStocks Nov. 10 at 9:07 PM
$CASI CASI Pharmaceuticals Receives and Appeals Delisting Determination from NASDAQ https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/casi-pharmaceuticals-receives-and-appeals-delisting-determination-fro-1099368 Delist letter received November 5. CASI appealed. The appeal will stay the suspension of the Company's securities pending the outcome of the appeal hearing.
0 · Reply
BillionerOfKing
BillionerOfKing Nov. 4 at 10:58 AM
$CASI Current Stock Price: $1.38 Contracts to trade: $2.5 CASI Nov 21 2025 Call Entry: $2.70 Exit: $5.02 ROI: 86% Hold ~25 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
DARKP00L
DARKP00L Nov. 3 at 2:44 PM
$CASI 09:15 on Nov. 03 2025 CASI Pharmaceuticals To Present Phase 1 CID-103 Data In Immune Thrombocytopenia At ASH 2025 #tradeideas
0 · Reply
eddiez69
eddiez69 Oct. 31 at 1:10 PM
$CASI This stock is on sale here at this price. I am buyer with limit orders. One piece of news and this will back over $2.00.
0 · Reply
Mr_Bill
Mr_Bill Oct. 29 at 7:34 PM
$CASI
0 · Reply
NVDAMillionaire
NVDAMillionaire Oct. 27 at 5:35 PM
$CASI Outstanding article that hits the mark on CASI's current state. So if you want to refresh your CASI insights or learn about CASI from scratch, this is a must read. https://beyondspx.com/quote/CASI/analysis/casi-pharmaceuticals-a-focused-future-on-cid-103-s-immunological-promise-nasdaq-casi
1 · Reply
eddiez69
eddiez69 Oct. 23 at 6:54 PM
$IMMX Volume on this indicates institutional accumulation. Long and strong! YO Small Cap Traders - you MUST LOOK at $CASI - mkt cap is $25.26 Million with only 1.84 Millions shares in float. The team is a who's who in biotech deals with David Cory, new CEO having brought many drugs to market and multiple Billion $ buyouts at other biotechs. Private Placement recently completed on 9/26 at higher price - Panacea and James Huang’s combined effective average cost is about $1.83 per share. No cash issues. Seriously big market for their drug. IMO this is a $7 stock easily See their 13D on edgar https://app.quotemedia.com/data/downloadFiling?webmasterId=102691&ref=319477051&type=HTML&symbol=CASI&cdn=9441db26338e6caf804c7ff41b11286b&companyName=CASI+Pharmaceuticals+Inc.&formType=SCHEDULE+13D&formDescription=General+statement+of+acquisition+of+beneficial+ownership&dateFiled=2025-09-26
0 · Reply
JGroove
JGroove Oct. 22 at 12:53 PM
$CASI guess I am bag holding until the next run
0 · Reply
JGroove
JGroove Oct. 15 at 3:24 PM
$CASI queued
0 · Reply
BullishPiggy
BullishPiggy Oct. 13 at 9:15 PM
$CASI whats this AH bullshit
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Oct. 9 at 8:00 PM
9/26/25 list Results $CACC $CASI $CADE $CAE $CAG 🔥 Cycle Trading Signal plugged into AI 🔥 list
0 · Reply
eddiez69
eddiez69 Oct. 8 at 4:40 PM
$IMMX This is easily a $200M to $400M market cap making it a potential $6 to $12 stock in the near-term. Check out $CASI also - its trading with just $30M market cap now with just 16M shares in the float- this is another one that could 3x to 5x in price
1 · Reply
StockScanners
StockScanners Oct. 4 at 3:41 PM
$CASI reached 2.07, lets go
0 · Reply
PharmaExpert
PharmaExpert Oct. 3 at 5:50 PM
$AKBA, $ANRO, $NEUP, $EVAX, $CASI 🔥🔥🔥🔥🔥
1 · Reply
StockScanners
StockScanners Oct. 3 at 2:56 AM
$CASI reached 1.92
0 · Reply
StockScanners
StockScanners Oct. 2 at 12:51 AM
$CASI reached 1.75
0 · Reply
jenyz20
jenyz20 Oct. 1 at 2:30 PM
$PALI $BBLG $CASI $ISPC $MSPR next swing watchlist posted 9/28 all hit but mspr
0 · Reply
Nova_Trades
Nova_Trades Oct. 1 at 5:37 AM
Winner Wednesday Watchlist Pt. 5: $QCLS $CASI $AKBA $MTEX $VIVK ⚡️ Closing out the month strong and stepping into a brand-new one tomorrow—fresh setups, fresh momentum, and fresh opportunities. Let’s make it count and level up from day one! 🚀📈
0 · Reply
Stock_Catcher
Stock_Catcher Oct. 1 at 1:25 AM
Winner Wednesday Watchlist Pt. 5 $QCLS $CASI $AKBA $MTEX $VIVK Brand New Month Tomorrow Let's GO! 🎃
0 · Reply
StockScanners
StockScanners Oct. 1 at 1:23 AM
$CASI keep watch if this holds above 1.45
0 · Reply